SARS-CoV-2 and Multiple Sclerosis: Not All Immune Depleting DMTs are Equal or Bad.

Amor, Sandra; Baker, David; Khoury, Samia J; Schmierer, Klaus; Giovanonni, Gavin

Amor, Sandra; Baker, David; Khoury, Samia J; Schmierer, Klaus; Giovanonni, Gavin.

Amor S; Pathology Department, VUMC, Amsterdam UMC, Amsterdam, The Netherlands.
Baker D; Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Khoury SJ; Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Schmierer K; Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA, USA.
Giovanonni G; Abu Haidar Neuroscience Institute, American University of Beirut, Beirut, Lebanon.

Ann Neurol ; 87(6): 794-797, 2020 06.

Article in English | MEDLINE | ID: covidwho-1384104

Subject(s)

Betacoronavirus; Coronavirus Infections/drug therapy; Immunosuppressive Agents/therapeutic use; Multiple Sclerosis/drug therapy; Pneumonia, Viral/drug therapy; Practice Guidelines as Topic/standards; Betacoronavirus/drug effects; Betacoronavirus/immunology; COVID-19; Coronavirus Infections/immunology; Humans; Immunosuppressive Agents/adverse effects; Multiple Sclerosis/immunology; Pandemics; Pneumonia, Viral/immunology; Severe acute respiratory syndrome-related coronavirus/drug effects; Severe acute respiratory syndrome-related coronavirus/immunology; SARS-CoV-2; Severe Acute Respiratory Syndrome/drug therapy; Severe Acute Respiratory Syndrome/immunology

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Practice Guidelines as Topic / Coronavirus Infections / Betacoronavirus / Immunosuppressive Agents / Multiple Sclerosis Type of study: Prognostic study Limits: Humans Language: English Journal: Ann Neurol Year: 2020 Document Type: Article Affiliation country: ANA.25770

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google